Haemoadsorption by CytoSorb® in patients with acute liver failure: A case series
- PMID: 33302765
- DOI: 10.1177/0391398820981383
Haemoadsorption by CytoSorb® in patients with acute liver failure: A case series
Abstract
Acute liver failure (ALF) is a life-threatening disease associated with multi-organ failure and increased mortality. Severe inflammation is now considered the main pathophysiological mechanism for organ dysfunction, thus rebalancing pro- and anti- inflammatory cytokines may improve liver function and outcome. The aim of this study was to assess the clinical effects of a haemoadsorption column on biochemical parameters in patients with ALF. We prospectively included 28 patients with ALF who were treated with three consecutive sessions of continuous venovenous haemofiltration in combination with CytoSorb®. Our results show an improvement in liver functional tests and a decrease in Creactive protein. Thrombocytopenia remains one of the most important side effects of this treatment and careful consideration should be made before initiation of treatment.
Keywords: Liver failure; acute liver failure; apheresis and detoxification techniques; artificial kidney; artificial liver; haemodiafiltration; immune disorders.
Comment in
-
The cytokine adsorber Cytosorb® does not reduce ammonia concentrations in critically ill patients with liver failure.Intensive Care Med. 2023 Mar;49(3):360-362. doi: 10.1007/s00134-023-06998-w. Epub 2023 Feb 10. Intensive Care Med. 2023. PMID: 36763124 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
